Medis Technologies Announces $29.0 Million Securities Offering

Medis Technologies Ltd. (NASDAQ:MDTL) announced today that it has entered into definitive agreements to sell securities to selected institutional investors for aggregate gross proceeds of $29,000,000. The offering is made pursuant to the Form S-3 shelf registration statement that was filed by Medis with the Securities and Exchange Commission (the "SEC”) and declared effective by the SEC on April 24, 2008. The offering is expected to close on or about June 24, 2008, subject to the satisfaction of customary closing conditions. Medis intends to use the net proceeds from the offering for working capital and general corporate purposes. The securities in the offering include up to 6,823,529 shares of Medis’ common stock and five year warrants to purchase up to 2,941,176 shares of Medis common stock at an exercise price of $5.50 per share. Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as the exclusive placement agent for the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offer will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the prospectus supplement together with the accompanying prospectus can be obtained at the SEC’s website at http://www.sec.gov or from Rodman & Renshaw, LLC, 1270 Avenue of the Americas, 16th Floor, New York, NY, 10020. About Medis Technologies Ltd. Medis Technologies’ primary focus is on its fuel cell technology. Its business strategy is to sell its products to end users through branded OEM partnerships, retail outlets, service providers and to the military and other markets. Medis’ majority-owned and publicly traded subsidiary, Cell Kinetics Ltd., is engaged in the development and commercialization of the CKChip, a unique cell carrier platform intended for simultaneous fluoroscopic monitoring and analysis of thousands of individual living cells over time. This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify those so-called "forward looking statements” by words such as "may,” "will,” "should,” "expects,” plans,” "targets,” "believes,” "anticipates,” "estimates,” "predicts,” "potential,” or "continue” or the negative of those words and other comparable words. These forward looking statements are subject to risks and uncertainties, product tests, commercialization risks, availability of financing and results of financing efforts that could cause actual results to differ materially from historical results or those anticipated. Further information regarding these and other risks is described from time to time in the Company’s filings with the SEC. We assume no obligation to update or alter our forward-looking statements made in this release or in any periodic report filed by us under the Securities Exchange Act of 1934 or any other document, whether as a result of new information, future events or otherwise, except as otherwise required by applicable federal securities laws. This press release is available on Medis’ web site at www.medistechnologies.com.